Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Natalizumab Stories

2012-12-28 05:02:45

Part 1: Overview, progress toward stopping MS. New York, NY (PRWEB) December 27, 2012 MS research continued to advance on many fronts in 2012. This year saw:     The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;     The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;...

2012-05-23 02:26:59

TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada has approved a product monograph change for TYSABRI® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help...

2012-02-22 06:00:00

BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY(TM) - a phase III study that will evaluate the efficacy and safety of Cimzia® (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate to severe rheumatoid arthritis (RA), who have not previously been treated with disease-modifying antirheumatic drugs (DMARDs). The study also aims to assess whether the...

2012-01-20 15:00:00

MADISON, N.J., Jan. 20, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV(TM) Antibody ELISA testing service. STRATIFY JCV is the first blood test to be FDA market authorized for the qualitative detection of antibodies to the polyomavirus JC virus (JCV) for stratifying risk for...

2012-01-20 14:45:00

SILVER SPRING, Md., Jan. 20, 2012 /PRNewswire-USNewswire/ -- Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease (CD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The Stratify JCV Antibody ELISA test, when used with other clinical data...

2011-12-21 00:00:00

BRUSSELS, Dec. 21, 2011 /PRNewswire/ -- UCB today announced the start of the EXXELERATE(TM) study which will evaluate the short- and long-term efficacy of Cimzia® (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira®* (adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans. "This head-to-head study is an important milestone. We believe that...

2011-12-08 10:03:00

National MS Society Live Webcast December 13 Will Offer MS News You Can Use From Internationally Renowned Researchers NEW YORK, Dec. 8, 2011 /PRNewswire-USNewswire/ -- This year saw exciting research progress in efforts to stop multiple sclerosis, restore function that's been lost and end the disease entirely. At least three emerging therapies are advancing through the pipeline toward FDA review while at least four clinical trials focusing on progressive MS continue to move...

2011-11-28 17:00:00

ProgressiveMultifocalLeukoencephalopathy.org aims to assist individuals in learning about PML. (PRWEB) November 28, 2011 Flood Law Group, LLP, a litigation firm, is announcing the launch of the new website, ProgressiveMultifocalLeukoencephalopathy.org, designed to assist individuals in learning about progressive multifocal leukoencephalopathy (PML), a disorder that harms the tissue surrounding the nerves in the brain and spinal cord. According to Flood Law Group, LLP, people who are...

2011-11-07 01:00:00

BRUSSELS and CHICAGO, Nov. 7, 2011 /PRNewswire/ -- UCB today announced findings from a post-hoc analysis suggesting that disease activity response rates to Cimzia(® )(certolizumab pegol) plus methotrexate (MTX) as early as Week 12 helped predict the effect on structural joint damage in patients with moderate to severe rheumatoid arthritis (RA) at one year. Comparable responses were found by both RAPID3 (Routine Assessment of Patient Index Data 3) and EULAR (European...

2011-10-31 09:00:00

ATLANTA, Oct. 31, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia® (certolizumab pegol) at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2. "Cimzia data presented this year at ACG highlights the role that inflammatory biomarkers may play in increasing the understanding of the...